Pulmonary surfactant is synthesized and secreted primarily by type II epithelial cells in the alveoli of the lung preventing atelectasis during the respiratory cycle. Deficiency or disruption of pulmonary surfactant causes respiratory distress syndrome. Surfactant consists not only of phospholipid, but it also contains several surfactant proteins including SP-A, 1 -B, -C, and -D that contribute to surfactant function and/or homeostasis. Surfactant proteins facilitate the spreading and enhance the stability of phospholipids in the alveoli and play an important role in host defense. SP-B is a 79-amino acid peptide that is derived by proteolytic processing of pro-SP-B in type II epithelial cells in the lung. SP-B plays a critical role in lamellar body and tubular myelin organization (1) (2) (3) (4) and is essential for postnatal respiratory adaptation after birth. Mutation of the SP-B gene in the human (h) and mouse causes respiratory failure at birth (5) (6) (7) . Even partial deficiency of SP-B in SP-Bϩ/Ϫ mice causes lung dysfunction and susceptibility to oxygen toxicity (8) .
Immunohistochemical staining and in situ hybridization studies indicate that SP-B mRNA and protein are restricted to type II cells and nonciliated bronchiolar epithelial cells in the lung (9 -11) . In vitro, the expression of SP-B is also restricted to cells of respiratory epithelial origins. The specificity of SP-B gene expression in pulmonary epithelial cells is primarily modulated at the level of gene transcription. Activities of multiple transcription factors on the SP-B promoter region contribute to the precise temporal-spatial distribution of SP-B gene expression in the lung. An enhancer region has been identified in the 5Ј-flanking region of the hSP-B gene (12) . Deletion of the enhancer dramatically reduced the hSP-B transcription activity in H441 cells. Three clustered DNA-binding sites of homeodomain-containing thyroid transcription factor 1 (TTF-1) have been identified in the enhancer region. Site-specific mutagenesis of the TTF-1 sites abolished enhancer activity completely (12) . TTF-1 is expressed in the lung, thyroid, and forebrain (13) . TTF-1 was originally identified in the thyroid where it controls the transcription of thyroperoxidase and thyroglobulin genes (14, 15) . In the lung, TTF-1 mRNA and protein were detected at the earliest stages of differentiation and were restricted to bronchial and alveolar epithelium in the postnatal lung (13) .
The hSP-B gene is also regulated by retinoic acids (RA) and their receptors (RAR). RA increased SP-B mRNA and pro-SP-B protein in H441 cells (16 -18) and lung explants in vitro (19, 20) . The responsiveness of RA stimulatory effect was identified within the enhancer region of the hSP-B promoter (16) . Furthermore, a dominant negative RAR␣403 mutant inhibited the hSP-B promoter in H441 cells, indicating an essential role of RAR in hSP-B promoter activity in respiratory epithelial cells (21) . The importance of the RA/RAR axis pathway in lung development is highlighted by the RAR␣/␤ double knock-out mouse which exhibited hypoplastic lungs (22) . In addition, RA altered branching morphogenesis of the lung in vitro (19, 20, 23) and may play a critical role in postnatal alveolarization in vivo (23, 24) . Supplementation of vitamin A from the early postnatal period reduced bronchopulmonary dysplasia-associ-ated morbidity in preterm infants (25) (26) (27) . Whereas the mechanisms by which RA affects lung development have not been fully clarified, expression of all three forms of RAR mRNAs was observed in the lung (28, 29) . RAR␣ protein was detected in the epithelium of the fetal mouse lung in day 14.5 gestation (21) . RAR␣ and -␥ and retinoic X receptor RXR␣ were also detected in the Clara cell-like H441 cell line (16) .
It is well established that RA and RAR play important roles in differentiation, growth, and homeostasis of epithelial cells in various tissues (30 -31) . RAR belongs to a large steroid/nonsteroid nuclear hormone receptor superfamily that consists of three receptor isotypes ␣, ␤, ␥, each encoded by distinct genes. RAR forms a heterodimer with (RXR) to bind to the retinoic acid-responsive element (RARE) on the target genes. Whereas RAR has weak DNA binding activity, RXR greatly enhanced RAR DNA binding activity through dimerization of RAR/RXR (33) . RAR consists of a DNA-binding domain that contains Zn 2ϩ finger motifs, a ligand-binding/dimerization domain, a ligand-independent AF-1 transcription activation domain, and a ligand-dependent AF-2 transcription activation domain. Through these various functional domains, RAR interacts with other transcription factors, including CBP/p300 and nuclear receptor coactivators. The first nuclear receptor coactivator identified was SRC-1 (34) . Several other coactivators were subsequently identified, including ACTR, TIF2, p/CIP, and p300/ CBP-associated factor (35) (36) (37) (38) (39) (40) . The interactions between RAR and coactivators are mediated by a well conserved amphipathic ␣-helix in the AF-2 domain of RAR (41, 42) . Many of these nuclear receptor coactivators contain two types of important functional domains. The receptor interaction domains contain NR box LXXL motifs that are required for direct interaction with nuclear receptors. Histone acetyltransferase (HAT) domains possess intrinsic histone acetylation activity (35, (43) (44) (45) . In addition to nuclear receptors, coactivators with HATs interact with each other to form a large transcription activation complex. Recruitment of multiple HATs leads to chromatin remodeling and target gene activation. In the absence of hormone ligands, nuclear receptors interact with corepressors, such as SMRT/TRAC and N-CoR/RIP13 to repress gene activation (46, 47) . These corepressors possess histone deacetylase activity (48) . Therefore, histone acetylation/deacetylation is critical to nuclear receptor signaling in epithelial cells.
MATERIALS AND METHODS
Plasmids-The hSP-B-500 construct was made previously (12) . The hSP-B 470 and hSP-B 417 constructs were generated by polymerase chain reaction (PCR) using Taq DNA polymerase (Life Technologies, Inc.), synthetic oligonucleotide primers, and the hSP-B 500 construct as a template.
The upstream primers with the MluI site for the hSP-B constructs were as follows: hSP-B 470 5Ј-CGCACGCGTAGGTGGTGAGAGTGTC-CTGG and hSP-B 417 5Ј-CGCACGCGTGCCAGGCAGGAAGCTCT. The downstream primer with the XhoI site was 5Ј-GCGCTCGAGCCACTG-CAGCAGGTGTGACTC.
The PCR products were digested with MluI and XhoI restriction enzymes (Life Technologies, Inc.) and ligated with MluI/XhoI-digested pGL2-B luciferase reporter plasmid (Promega). To generate the sitespecific mutants of the hSP-B-500 construct at the RARE/S1, S2, S3, and S1/S3 sites, two steps of PCR were conducted. For the first PCR, mutant PCR oligonucleotides were synthesized with mutations at the positions identical to the EMSA studies. The mutant primers were mixed with hSP-B 500 and primer GLprimer 1/GLprimer 2 (Promega) to make two sets of PCR products that were subsequently purified by low melting point agarose gel electrophoresis and the QIAquick gel extraction kit. The purified two sets of PCR products were then mixed together along with GLprimer 1 and GLprimer 2 primers for the second PCR. The second PCR products were digested with MluI/XhoI restriction enzymes. The DNA fragments with MluI-and XhoI-flanking sites at each end were purified by low melting point gel electrophoresis as described above and ligated into the MluI/XhoI-digested pGL2-B plasmid. Mutant constructs at TTF-1 sites were made previously (12) .
To make SV40/hSP-B(Ϫ331 to Ϫ500), the upstream primer 5Ј-CG-CACGCGTCAGAAGATTTTTCCAGGGGA with the MluI site and the downstream primer 5Ј-GCGCTCGAGGCCTGGGTGTTCCCCTCCCAT with the XhoI site were used to amplify the wild type hSP-B 500 as a template by PCR. The PCR product was purified, digested, and ligated into pGL-2 P (Promega) MluI/XhoI site. The correctness of all plasmid constructs was confirmed by DNA sequencing. The ACTR expression vector (35) , the SRC-1 expression vector (34), RAR␣, RXR␥, and TIF-2 expression vectors (40) , and the CBP expression vector (49) were from the original authors.
Cell Culture-Human pulmonary adenocarcinoma cells (H441) were cultured in RPMI supplemented with 10% fetal calf serum, glutamine, and penicillin/streptomycin. Cells were maintained at 37°C in 5% CO 2 /air and passaged weekly.
Transfection and Reporter Gene Assays-For hSP-B promoter deletion and mutation studies, transient transfection and luciferase reporter assays were performed as described previously (12, 50) with minor modification. Briefly, H441 cells were seeded at densities of 2 ϫ 10 5 cells per well in 6-well plates. The hSP-B reporter constructs (0.25 g) hSP-B500, hSP-B470, hSP-B417, and mutation constructs hSP-B500/S1, hSP-B500/S2, hSP-B500/S3, and hSP-B500/S1/S3 were transfected with 0.5 g of pCMV-␤gal plasmid into H441 cells by Fugene6 (Roche Molecular Biochemicals). After 2 days of incubation with and without all-trans-RA (10 Ϫ5 M), cells were lysed, and luciferase activities were performed using the luciferase assay system (Promega). The light units were assayed by luminometry (Monolight 3010, Analytical Luminescence Laboratory, San Diego, CA). In each transfection, ␤-galactosidase activities were determined for normalization of transfection efficiency. For the SV40/hSP-B(Ϫ500/Ϫ331) luciferase reporter gene studies, transient transfection and luciferase reporter assays were performed as outlined above, except the SV40 and SV40/hSP-B(Ϫ500/ Ϫ331) luciferase constructs were used. To determine the stimulatory effects of RAR␣/RXR␥, nuclear receptor coactivators, CBP, and TTF-1, various expression constructs were cotransfected with the hSP-B 500 luciferase reporter construct as specified in the figure legends and 0.5 g of pCMV-␤gal plasmid included for normalization of transfection efficiency. Carrier DNA plasmids were utilized to keep the total DNA concentrations constant for all points.
Mammalian Two-hybrid System Assay-The plasmid constructs of pVP16/TTF-1 AD, pM/RAR␣ BD, and pM/TIF2 BD were made by subcloning the PCR products of TTF-1, RAR␣, and TIF2 molecules into pM and pV16 vectors (CLONTECH, Palo Alto, CA 94304) at the EcoRI/XbaI sites. The reporter construct PG5LUC was generated by subcloning of GAL4-binding sites (UAS G 17-mer(ϫ5) ) and an adenovirus E1b minimal promoter into the pGL2-B luciferase reporter gene at the MluI/XhoI sites. Two hybrid cotransfections of above plasmid constructs in H441 cells were performed as recommended by the manufacturer (CLONTECH).
EMSA-Wild type and mutant double-stranded Oligo1 (Ϫ438 to Ϫ470) and Oligo2 (Ϫ410 to Ϫ439) of the hSP-B enhancer region were synthesized, annealed, and purified as follows: wild type Oligo1, 5ЈAG-GTGGTGAGAGTGTCCTGGGTCTGCCCTTCCA3Ј; mutant Oligo1, 5ЈAGGTGGTGAGAGacgataGGGTCTcgattTTCCA3Ј; wild type Oligo2, 5ЈCAGGGCTTGCCCTGGGTTAAGAGCCAGGCA3Ј; and mutant Oligo2, 5ЈCAGGGCTTGgatgGGGTTAAGAGCCAGGCA3Ј.
The underlined sequences represent the wild type or mutant RAREs. The oligonucleotides were radiolabeled by [␥-
32 P]ATP and kinase and incubated with 100 ng of the purified RAR␥-GST fusion protein as suggested by the manufacturer (Santa Cruz Biotechnology). EMSA was performed by following the procedures described previously (12) . In the absence of RXR, relatively higher concentrations of RAR proteins were required due to low DNA binding affinity of RAR. Polyclonal antibody against RAR (1 g) (Santa Cruz Biotechnology) was used in the supershift assays.
Immunocytochemistry-Alveolar type II epithelial cells were isolated from adult mice following the procedure described previously (51) . Cells were seeded onto Permanox chamber slides (Fisher) at densities ranging from 10 4 to 10 5 cells per chamber (two chambers per slide) by cytospin. For immunocytostaining of RAR proteins, the procedure followed the previous publication using RAR␣, -␤, and -␥ antibodies (Santa Cruz Biotechnology) (16) .
RESULTS

RAR␣ Expression in Alveolar Type II Epithelial Cells-SP-B
mRNA and protein are present in non-ciliated bronchiolar cells and in alveolar type II epithelial cells in the lung parenchyma (52) . All three RAR␣, -␤, and -␥ isotypes stimulated hSP-B promoter activity and RAR␣ and -␥ expression were detected in the bronchiolar Clara cell-like H441 adenocarcinoma cell line (16) .
TTF-1, RAR, and Coactivator Stimulation of the hSP-B Gene
Immunocytochemical staining of primary isolates of mouse alveolar type II cells with antibodies specifically against RAR␣, -␤, and -␥ demonstrated that only the RAR␣ isotype was expressed in primary isolates of mouse alveolar type II epithelial cells (Fig.  1) . Therefore, RAR␣ but not RAR␤ plays a role in regulating hSP-B gene expression in distal respiratory epithelial cells.
RAR␣ Stimulates the hSP-B Promoter in H441 Cells-Since RAR␣ was detected in both type II epithelial cells and H441 cells, its effect on the activity of the hSP-B promoter was assessed in vitro. RAR␣ was cotransfected with equal concentrations of RXR␥ and 0.25 g of the hSP-B 500 luciferase reporter construct into H441 cells. RAR␣/RXR␥ stimulated the hSP-B 500 luciferase reporter construct in H441 cells (Fig. 2) . Stimulatory effects were dose-dependent and further enhanced by alltrans-RA (10 Ϫ5 M), indicating that hSP-B 500 contains RAREs.
Interactions between RAR Protein and RAREs of the hSP-B
Promoter-Homology search revealed that the hSP-B Ϫ417 to Ϫ470 region contains three potential RARE sites (RARE/S1, RARE/S2, and RARE/S3) that resemble the core motifs of RAREs (TGCCCG or TGTCCT) in the 5Ј-flanking region of the retinol-binding protein gene (53) (Fig. 4A) . To assess whether these sites bind RAR proteins, two synthetic double-stranded oligonucleotides (Oligo1 and Oligo2) containing these sites were synthesized and radiolabeled for EMSA analysis. Oligo1 (Ϫ438 to Ϫ470 bp) contains both RARE/S1 and RARE/S2 sites. Oligo2 (Ϫ410 to Ϫ439 bp) contains the RARE/S3 site. As demonstrated in Fig. 3 , both Oligo1 and Oligo2 formed DNA-protein complexes with the purified RAR protein in the EMSA study. The DNA-RAR complexes were specific and supershifted by a polyclonal antibody recognizing RAR. The antibody alone did not form complexes with the oligonucleotides (data not shown). When mutations were introduced into the potential RARE sites in Oligo1 and Oligo2, only a nonspecific band was observed, indicating these sites are required for RAR DNA binding.
Deletion and Mutation Analysis of RAREs on the hSP-B Promoter-To assess whether RARE sites in the enhancer region mediate the stimulatory effect of all-trans-RA on the hSP-B promoter, hSP-B 470 that contains all three putative RARE sites, and hSP-B 417 that lacks RARE sites was cotransfected into H441 cells in the presence or absence of all-trans-RA (10 Ϫ5 M). Whereas hSP-B 470 was still stimulated by alltrans-RA in H441 cells, deletion of the region Ϫ417 to Ϫ470 (hSP-B 417) caused complete loss of all-trans-RA stimulation (Fig. 4A) . Single mutations RARE/S1, RARE/S2, and RARE/S3 partially inhibited the stimulatory effects of RA on hSP-B 500, whereas double mutations RARES1/S3 completely abolished RA stimulation of the hSP-B 500 promoter (Fig. 4B) , demonstrating that these RARE clustered sites are essential for RA stimulation of the hSP-B promoter. Radiolabeled wild type (wt) and mutant (mt) Oligo1 and Oligo2 probes were incubated with the purified RAR␥-GST fusion protein (100 g). Oligo1 represents hSP-B(Ϫ438/Ϫ470). Oligo2 represents hSP-B(Ϫ410/Ϫ439). Free probes and DNAprotein complexes were separated on 4% nondenaturing polyacrylamide gels. RAR antibody (Ab) (1 g) was included to supershift DNA-protein complexes. Arrows indicate RAR-DNA complex formations and supershifts.
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expression. Since RA and RAR stimulate the hSP-B promoter, we reasoned that these coactivators may interact with RAR to stimulate the hSP-B promoter. In cotransfection and luciferase assay, three such coactivators, ACTR, SRC-1, and TIF-2, significantly stimulated the hSP-B 500 promoter in H441 cells (Fig. 5) . Stimulation of hSP-B promoter activity by each coactivator was dose-dependent.
Synergistic Stimulation of the hSP-B Gene in H441
Cells by CBP and RAR-In addition to interaction with nuclear receptor coactivators, RAR interacts with CBP, a common and ratelimiting mediator in many signaling pathways (38) . CBP also interacts with nuclear receptor coactivators (35, 38 -40) . Whereas CBP itself only modestly stimulated hSP-B 500 (2-3-fold) (Fig. 6A) , cotransfection of hRAR␣/hRXR␥ and CBP markedly stimulated hSP-B 500 (13-fold) in H441 cells (Fig. 6B) . hRAR␣/hRXR␥ alone increased activity of the hSP-B 500 promoter 4-fold. The combinatorial effect of CPB and hRAR␣/ hRXR␥ was greater than additive (13-versus 6-fold).
RA Stimulation of the hSP-B Promoter Is TTF-1 Site-dependent-There are three previously identified TTF-1 sites in the hSP-B enhancer region (12) . These TTF-1 sites are required for enhancer stimulatory activity. Interestingly, the clustered TTF-1 sites are located in close juxtaposition to the clustered RARE sites in the enhancer region of the hSP-B promoter. To test if the clustered TTF-1 sites are required for RA stimulatory activity on the hSP-B promoter, the wild type and three TTF-1 site mutants of hSP-B500 were transfected into H441 cells and treated with all-trans-RA (10 Ϫ5 M), respectively. As demonstrated in Synergistic Stimulation of hSP-B500 by TTF-1, RAR␣, and Nuclear Receptor Coactivators-Since TTF-1-binding sites in the enhancer region are required for RA stimulation of hSP-B500, combinatorial stimulatory effects between TTF-1 and RAR, CBP or coactivators were characterized in cotransfection studies (Table I ). The effect of TTF-1 and RAR␣ stimulation of hSP-B 500 were synergistic rather than additive increasing activity (11.8 versus 5.1-fold) in the luciferase reporter assay. The synergistic effect was strongest between TTF-1 and TIF2 (15.0-versus 5.3-fold). Strong synergy was noted between TTF-1 and SRC-1 or ACTR (10.2 versus 4.4-fold and 8.6 versus 5.1-fold, respectively), whereas synergy between TTF-1 and CBP was modest (5.8-versus 4.2-fold).
Interactions between TTF-1 and RAR␣/TIF2 in the Mammalian Two-hybrid System-To prove further that TTF-1 interacts with RAR and coactivators, TTF-1 was subcloned into the pVP16 vector containing the VP16 activation domain (AD), and RAR␣ and TIF2 were subcloned into the pM vector containing the GAL4-binding domain (BD). The pVP16/TTF-1 AD, pM/ RAR␣ BD, and pM/TIF2 BD constructs were transfected alone or cotransfected into H441 cells. The luciferase reporter construct pG5LUC containing five GAL4-binding sites was also cotransfected into H441 cells to monitor the protein-protein interactions. When compared with transfection of pVP16/ TTF-1 AD, pM/RAR␣ BD, or pM/TIF2 BD alone, luciferase activities were markedly increased in cotransfection with the pair of pVP16/TTF-1 AD and pM/RAR␣ BD, and with the pair of pVP16/TTF-1 AD and pM/TIF2 BD, respectively (Fig. 8) . Sites of the hSP-B Promoter-In addition to the clustered TTF-1 sites located in the enhancer region, two more TTF-1 sites were identified downstream the enhancer region, located between Ϫ73 and Ϫ111 bp of the hSP-B promoter (54) . To test if these TTF-1 sites are required for RA stimulation of the hSP-B promoter, a hSP-B(Ϫ331 to Ϫ500) fragment lacking the downstream TTF-1 sites was subcloned upstream of an SV40 promoter luciferase reporter gene. The SV40/hSP-B(Ϫ331 to Ϫ500) luciferase construct and the SV40 basic promoter luciferase construct (control) were transfected into H441 cells to study RA and RAR/RXR stimulatory effects (Fig. 9) . The luciferase activity of SV40/hSP-B(Ϫ331 to Ϫ500) was induced 3-4-fold by all-trans-RA (10 Ϫ5 M), whereas the SV40 promoter alone was not affected by all-trans-RA. Even though hRAR␣/hRXR␥ stimulated the activity of the SV40 promoter, the enhanced activity was not RA-dependent and was reduced by all-trans-RA. It has been reported that RAR contains ligand-independent transactivation domains (30, 32,) . On the other hand, all-trans-RA dramatically stimulated the SV40/hSP B(Ϫ331 to Ϫ500) activity (31-fold) when cotransfected with hRAR␣/hRXR␥. Therefore, the downstream TTF-1 sites of the hSP-B promoter are not required for RA stimulation mediated by the hSP-B enhancer. Of interest, the clustered RARE and TTF-1 sites of the hSP-B enhancer had 
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much stronger RA stimulatory effect on the SV40 promoter than that of the hSP-B promoter (31-versus 8-fold).
DISCUSSION
Multiple signaling pathways regulate hSP-B gene transcription or mRNA stability in respiratory epithelial cells (12, 54 -58) . In previous studies, RA stimulated hSP-B gene expression (16, 17, 19, 20) . It is generally believed that the DNA consensus sequences located in the promoter and enhancer regions of target genes mediate cellular signaling pathways through binding sequence-specific transcription factors. Previous studies identified an enhancer region located between Ϫ331 to Ϫ500 bp of the hSP-B gene, which strongly regulates SP-B gene transcription (12) . This enhancer region is well conserved among species, with human and murine genes sharing 95% homology in this region. Further characterization demonstrated that the enhancer region of the hSP-B promoter contains three TTF-1 sites (12) . In the present study, three clustered RARE sites were identified in the enhancer region located immediately upstream of the TTF-1 sites to regulate the response of the hSP-B promoter to RA.
A direct repetition of two core motifs ((A/G)G(G/T)TCA) was identified as essential for RAR and RXR binding (classical RARE). The spacing (DR1, DR3, DR4, and DR5) and orientation of the repeated core motifs are thought to determine the DNA binding specificity of some nuclear receptors (59) . This rule seems not very restrictive since inverted and reverted repeats with different DRs in several natural promoters are able to bind to RAR (60) . The polarity of the RAR/RXR dimer in DNA binding appears to be an important factor in determining gene specificity (61) (62) (63) . A sequence in the hSP-B enhancer region shares some degree of homology to the direct repetition of the classic RARE (16) . However, mutagenesis in the core motifs of the direct repetition in the sequence still retained RAR binding activity (data not shown). RARE sequences other than the classic (A/G)G(G/T)TCA are able to bind to the RAR/ RXR dimer and mediate RA function. One example is the retinol-binding protein gene. In its promoter region, sequences TGTCCT and TGCCCG bound to and determined RAR/RXR stimulation (53) . Three such identical consensus sequences were identified in the hSP-B enhancer region (Fig. 4) . Although RAREs (S1, S2, and S3) were bound to RAR, single mutations in the RARE clustered sites partially impaired RA stimulatory activity in the hSP-B promoter, whereas deletion of all three RARE sites or mutations of two RARE sites (S1/S3) resulted in complete loss of RA stimulation (Fig. 4) .
There are three isotypes (␣, ␤, and ␥) of RAR mediating RA function in cells. Immunohistochemistry study demonstrated that only RAR␣ was detected in mouse type II epithelial cells where SP-B is synthesized and processed (Fig. 1) . This finding is in agreement with our previous findings that RAR␣ was detected in the epithelium of the fetal mouse lung (21) and in H441 cells that share characteristics of non-ciliated bronchiolar cells (16) . Therefore, RAR␣ may play a role in mediating RA signaling in the distal airways. In contrast, RAR␤ is expressed in the tracheal epithelium and mesenchyme early in fetal development and continues to be expressed in the newly formed proximal airways but is excluded from the distal respiratory epithelium (28) . RAR␤ gene expression may represent an early marker of mucosecretory differentiation of normal human bronchial epithelial cells (64) .
In addition to interacting directly with basal transcription factors, RAR has another important function, recruiting nuclear receptor coactivators in the presence of RA. These nuclear receptor coactivators physically interact with the AF-2 domain of RAR in a ligand-dependent fashion and are expressed in the lung (34, 35, 39, 40) . The present study demonstrates that nuclear receptor coactivators SRC-1, TIF2, and ACTR significantly stimulated the hSP-B promoter (Fig. 5) . Many of these coactivators have intrinsic histone acetyltransferase activity that is involved in remodeling chromatin structure during gene activation. CBP physically interacts with RAR/RXR and their coactivators (35, 38 -40) . Although CBP had a modest stimulatory effect on the hSP-B promoter in H441 cells, cotransfection of CBP and RAR/RXR synergistically stimulated hSP-B luciferase reporter activity (Fig. 6) , indicating interactions between CBP, RAR/RXR, and coactivators in pulmonary epithelial cells. Like nuclear receptor coactivators, CBP has intrinsic histone acetyltransferase activity (43, 44) .
Although the RA/RAR signaling pathway is well known to be critical to epithelial cell differentiation and proliferation in a variety of tissues, little is known about how this pathway interacts with and is determined by tissue-specific factors in a particular organ system. The present study demonstrated that in the pulmonary epithelial system, RA stimulation of the hSP-B promoter through RARE sites is dependent on the juxtaposed clustered TTF-1 sites in the enhancer region of the hSP-B promoter because mutations at these sites reduced or abolished RA stimulation (Fig. 7) . In addition, TTF-1 interacts with RAR␣ and TIF2 in the mammalian two-hybrid system (Fig. 8) . TTF-1 also synergistically stimulated hSP-B500 with RAR␣, SRC-1, TIF2, ACTR, and CBP (Table I) , strongly suggesting the involvement and requirement of TTF-1 in the formation of the RAR⅐CBP⅐coactivators complex in the enhancer region of the hSP-B promoter. The downstream TTF-1 sites (Ϫ73 to Ϫ111 bp) of the hSP-B promoter seem not to be required for RA stimulation. After separation from the downstream TTF-1 sites, the clustered RARE sites in the enhancer region still rendered the SV40 promoter responsive to stimulation by RA (Fig.  9) . Therefore, the upstream enhancer works as an independent unit in which the tissue-specific factor TTF-1 determines RA/ RAR signaling activity in pulmonary epithelial cells. The RAR⅐RXR⅐TTF-1⅐CBP⅐coactivator complex in the enhancer region of the SP-B gene may play an important role in the temporal and spatial expression of SP-B during lung development.
